NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

British Journal of Haematology

Volumn 168, Issue 5, 2015, Pages 679-688

  Varga, Gergely ^a   Mikala, Gábor ^b   Andrikovics, Hajnalka ^c   Koszarska, Magdalena ^c   Balassa, Katalin ^c   Ádám, Emma ^b   Kozma, András ^b   Tordai, Attila ^c   Masszi, Tamás ^a,b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b Szent Laszlo Hospital   (Hungary)

^c Hungarian National Blood Transfusion Service   (Hungary)

Author keywords

NFKB1; Bortezomib; Multiple myeloma; Nuclear factor kappa B; Polymorphism

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; NFKB1 PROTEIN, HUMAN; PYRAZINE DERIVATIVE; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ALLELE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENE DELETION; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BORONIC ACIDS; DISEASE-FREE SURVIVAL; FEMALE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NF-KAPPA B P50 SUBUNIT; POLYMORPHISM, GENETIC; PYRAZINES; RETROSPECTIVE STUDIES; SEQUENCE DELETION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84922767744     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13197     Document Type: Article

References (33)

1. Aggarwal, B.B. & Sung, B. (2011) NF-kappaB in cancer: a matter of life and death. Cancer Discovery, 1, 469-471.
2. Annunziata, C.M., Davis, R.E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., Dave, S., Hurt, E.M., Tan, B., Zhao, H., Stephens, O., Santra, M., Williams, D.R., Dang, L., Barlogie, B., Shaughnessy, J.D. Jr, Kuehl, W.M. & Staudt, L.M. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell, 12, 115-130.
3. Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., Marit, G., Michaux, L., Voillat, L., Renaud, M., Grosbois, B., Guillerm, G., Benboubker, L., Monconduit, M., Thieblemont, C., Casassus, P., Caillot, D., Stoppa, A.M., Sotto, J.J., Wetterwald, M., Dumontet, C., Fuzibet, J.G., Azais, I., Dorvaux, V., Zandecki, M., Bataille, R., Minvielle, S., Harousseau, J.L., Facon, T. & Mathiot, C. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood, 109, 3489-3495.
4. Bauer, S., Parry, J.A., Muhlenberg, T., Brown, M.F., Seneviratne, D., Chatterjee, P., Chin, A., Rubin, B.P., Kuan, S.F., Fletcher, J.A., Duensing, S. & Duensing, A. (2010) Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Research, 70, 150-159.
5. Borm, M.E., van Bodegraven, A.A., Mulder, C.J., Kraal, G. & Bouma, G. (2005) A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. International Journal of Immunogenetics, 32, 401-405.
6. Cavo, M., Pantani, L., Petrucci, M.T., Patriarca, F., Zamagni, E., Donnarumma, D., Crippa, C., Boccadoro, M., Perrone, G., Falcone, A., Nozzoli, C., Zambello, R., Masini, L., Furlan, A., Brioli, A., Derudas, D., Ballanti, S., Dessanti, M.L., De Stefano, V., Carella, A.M., Marcatti, M., Nozza, A., Ferrara, F., Callea, V., Califano, C., Pezzi, A., Baraldi, A., Grasso, M., Musto, P., Palumbo, A. & for GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network (2012) Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood, 120, 9-19.
7. Dolcet, X., Llobet, D., Encinas, M., Pallares, J., Cabero, A., Schoenenberger, J.A., Comella, J.X. & Matias-Guiu, X. (2006) Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. Journal of Biological Chemistry, 281, 22118-22130.
8. Du, J., Huo, J., Shi, J., Yuan, Z., Zhang, C., Fu, W., Jiang, H., Yi, Q. & Hou, J. (2011) Polymorphisms of nuclear factor-kappaB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica, 96, 729-737.
9. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G., Rajkumar, S.V. & International Myeloma Working Group. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
10. Harousseau, J.L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., Michallet, M., Maisonneuve, H., Benboubker, L., Maloisel, F., Petillon, M.O., Webb, I., Mathiot, C. & Moreau, P. (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. Journal of Clinical Oncology, 28, 4621-4629.
11. Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N.C., Richardson, P.G., Carrasco, R.D. & Anderson, K.C. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood, 114, 1046-1052.
12. Karban, A.S., Okazaki, T., Panhuysen, C.I., Gallegos, T., Potter, J.J., Bailey-Wilson, J.E., Silverberg, M.S., Duerr, R.H., Cho, J.H., Gregersen, P.K., Wu, Y., Achkar, J.P., Dassopoulos, T., Mezey, E., Bayless, T.M., Nouvet, F.J. & Brant, S.R. (2004) Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Human Molecular Genetics, 13, 35-45.
13. Karin, M. (2006) Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431-436.
14. Keats, J.J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.J., Van Wier, S., Tiedemann, R., Shi, C.X., Sebag, M., Braggio, E., Henry, T., Zhu, Y.X., Fogle, H., Price-Troska, T., Ahmann, G., Mancini, C., Brents, L.A., Kumar, S., Greipp, P., Dispenzieri, A., Bryant, B., Mulligan, G., Bruhn, L., Barrett, M., Valdez, R., Trent, J., Stewart, A.K., Carpten, J. & Bergsagel, P.L. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell, 12, 131-144.
15. Lenhoff, S., Hjorth, M., Holmberg, E., Turesson, I., Westin, J., Nielsen, J.L., Wisloff, F., Brinch, L., Carlson, K., Carlsson, M., Dahl, I.M., Gimsing, P., Hippe, E., Johnsen, H.E., Lamvik, J., Lofvenberg, E., Nesthus, I. & Rodjer, S. (2000) Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood, 95, 7-11.
16. Lewander, A., Butchi, A.K., Gao, J., He, L.J., Lindblom, A., Arbman, G., Carstensen, J., Zhang, Z.Y., Sun, X.F. & Swedish Low-Risk Colorectal Cancer Study Group. (2007) Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scandinavian Journal of Gastroenterology, 42, 1332-1338.
17. Li, H., Gao, L., Shen, Z., Li, C.Y., Li, K., Li, M., Lv, Y.J., Li, C.X., Gao, T.W. & Liu, Y.F. (2008) Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Archives of Dermatological Research, 300, 425-433.
18. Li, P., Gu, J., Yang, X., Cai, H., Tao, J., Yang, X., Lu, Q., Wang, Z., Yin, C. & Gu, M. (2013) Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PLoS One, 8, e71604.
19. Monconduit, M., Le Loet, X., Bernard, J.F. & Michaux, J.L. (1986) Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma. British Journal of Haematology, 63, 599-601.
20. Morgan, G.J., Davies, F.E., Gregory, W.M., Russell, N.H., Bell, S.E., Szubert, A.J., Navarro Coy, N., Cook, G., Feyler, S., Byrne, J.L., Roddie, H., Rudin, C., Drayson, M.T., Owen, R.G., Ross, F.M., Jackson, G.H., Child, J.A. & NCRI Haematological Oncology Study Group. (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood, 118, 1231-1238.
21. Oakervee, H.E., Popat, R., Curry, N., Smith, P., Morris, C., Drake, M., Agrawal, S., Stec, J., Schenkein, D., Esseltine, D.L. & Cavenagh, J.D. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology, 129, 755-762.
22. Oltulu, Y.M., Coskunpinar, E., Ozkan, G., Aynaci, E., Yildiz, P., Isbir, T. & Yaylim, I. (2014) Investigation of NF- kappa B1 and NF- kappa BIA Gene Polymorphism in Non-Small Cell Lung Cancer. Biomed Research International, 2014, 530381.
23. Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., Benevolo, G., Callea, V., Baldini, L., Morabito, F., Grasso, M., Leonardi, G., Rizzo, M., Falcone, A.P., Gottardi, D., Montefusco, V., Musto, P., Petrucci, M.T., Ciccone, G. & Boccadoro, M. (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of Clinical Oncology, 28, 5101-5109.
24. Palumbo, A., Rajkumar, S.V., San Miguel, J.F., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H., Anderson, K.C., Dimopoulos, M.A., Richardson, P.G., Cavo, M., Spencer, A., Stewart, A.K., Shimizu, K., Lonial, S., Sonneveld, P., Durie, B.G., Moreau, P. & Orlowski, R.Z. (2014) International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. Journal of Clinical Oncology, 32, 587-600.
25. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M., Greipp, P.R. & Eastern Cooperative Oncology Group. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology, 11, 29-37.
26. Richardson, P.G., Hideshima, T. & Anderson, K.C. (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control: Journal of the Moffitt Cancer Center, 10, 361-369.
27. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D., Anderson, K.C. & Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
28. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H., Richardson, P.G. & VISTA Trial Investigators. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
29. Szamosi, T., Lakatos, P.L., Hungarian, I.B.D.S.G., Szilvasi, A., Lakatos, L., Kovacs, A., Molnar, T., Altorjay, I., Papp, M., Szabo, O., Satori, A., Tulassay, Z., Miheller, P., Horvath, H.C., Papp, J., Tordai, A. & Andrikovics, H. (2009) The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patients. Digestive Diseases and Sciences, 54, 351-359.
30. Vangsted, A.J., Klausen, T.W., Gimsing, P., Andersen, N.F., Abildgaard, N., Gregersen, H. & Vogel, U. (2009) A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica, 94, 1274-1281.
31. Zhang, P., Wei, Q., Li, X., Wang, K., Zeng, H., Bu, H. & Li, H. (2009) A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genetics and Cytogenetics, 191, 73-77.
32. Zhou, B., Rao, L., Li, Y., Gao, L., Wang, Y., Chen, Y., Xue, H., Song, Y., Peng, Y., Liao, M. & Zhang, L. (2009) A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Letters, 275, 72-76.
33. Zou, Y.F., Yuan, F.L., Feng, X.L., Tao, J.H., Ding, N., Pan, F.M. & Wang, F. (2011) Association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis. Cancer Investigation, 29, 78-85.